MX349601B - Remocion de virus contaminantes de preparaciones de aav. - Google Patents

Remocion de virus contaminantes de preparaciones de aav.

Info

Publication number
MX349601B
MX349601B MX2014002733A MX2014002733A MX349601B MX 349601 B MX349601 B MX 349601B MX 2014002733 A MX2014002733 A MX 2014002733A MX 2014002733 A MX2014002733 A MX 2014002733A MX 349601 B MX349601 B MX 349601B
Authority
MX
Mexico
Prior art keywords
removal
viruses
contaminating viruses
aav preparations
aav
Prior art date
Application number
MX2014002733A
Other languages
English (en)
Other versions
MX2014002733A (es
Inventor
Theodorus Johannes Maria Christiaan Hermens Wilhelmus
patrick smith James
Original Assignee
Uniqure Ip Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47832422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX349601(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Uniqure Ip Bv filed Critical Uniqure Ip Bv
Publication of MX2014002733A publication Critical patent/MX2014002733A/es
Publication of MX349601B publication Critical patent/MX349601B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06—Organic material
    • B01D71/08—Polysaccharides
    • B01D71/10—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2623—Ion-Exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2649—Filtration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

La presente invención se refiere a una separación de virus de una forma esencialmente esférica de virus con una forma tipo barra que están comprendidos en una muestra, en donde la muestra que comprende los virus está sujeta a filtración.
MX2014002733A 2011-09-08 2012-09-07 Remocion de virus contaminantes de preparaciones de aav. MX349601B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532176P 2011-09-08 2011-09-08
EP11180594 2011-09-08
PCT/NL2012/050619 WO2013036118A1 (en) 2011-09-08 2012-09-07 Removal of contaminating viruses from aav preparations

Publications (2)

Publication Number Publication Date
MX2014002733A MX2014002733A (es) 2014-07-14
MX349601B true MX349601B (es) 2017-08-04

Family

ID=47832422

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002733A MX349601B (es) 2011-09-08 2012-09-07 Remocion de virus contaminantes de preparaciones de aav.

Country Status (20)

Country Link
US (3) US9840694B2 (es)
EP (3) EP2990477B8 (es)
JP (2) JP6198278B2 (es)
KR (1) KR101961347B1 (es)
CN (2) CN107502597A (es)
AU (1) AU2012304993B2 (es)
BR (1) BR112014005255A2 (es)
CA (1) CA2847604A1 (es)
DK (1) DK2744895T3 (es)
EA (1) EA027511B1 (es)
ES (1) ES2558168T3 (es)
HK (1) HK1220229A1 (es)
HU (1) HUE026579T2 (es)
IL (1) IL231398A (es)
MX (1) MX349601B (es)
PL (1) PL2744895T3 (es)
PT (1) PT2744895E (es)
SI (1) SI2744895T1 (es)
WO (1) WO2013036118A1 (es)
ZA (1) ZA201401714B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840694B2 (en) * 2011-09-08 2017-12-12 Uniqure Ip B.V. Removal of contaminating viruses from AAV preparations
CN105745326A (zh) 2013-10-24 2016-07-06 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
CN107109407A (zh) 2014-11-14 2017-08-29 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
BR112017013573A2 (pt) 2014-12-24 2018-03-06 Uniqure Ip Bv rna de cadeia dupla, sequência de dna, cassete de expressão, vetor de terapia de gene, e, célula hospedeira.
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
IL262784B2 (en) 2016-05-18 2023-10-01 Voyager Therapeutics Inc modulatory polynucleotides
CA3035522A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND TREATMENT METHODS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
WO2019079240A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
US20200354744A1 (en) 2018-01-17 2020-11-12 Meiragtx Uk Ii Limited Modified raav capsid protein for gene therapy
WO2020053258A1 (en) 2018-09-12 2020-03-19 Uniqure Ip B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd
WO2020104435A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. A companion diagnostic to monitor the effects of gene therapy
CA3120177A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. Method and means to deliver mirna to target cells
CA3121010A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3
WO2020104480A1 (en) 2018-11-19 2020-05-28 Uniqure Biopharma B.V. Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
TW202045529A (zh) 2019-02-15 2020-12-16 美商聖加莫治療股份有限公司 用於生產重組aav之組合物及方法
WO2020219897A1 (en) * 2019-04-24 2020-10-29 Biogen Ma Inc. Methods for production of recombinant adeno-associated viruses
MX2022000551A (es) 2019-07-15 2022-05-18 Meiragtx Uk Ii Ltd Proteínas de la cápside de aav modificadas para el tratamiento de una enfermedad artrítica.
EP4031148A1 (en) 2019-09-16 2022-07-27 uniQure IP B.V. Targeting misspliced transcripts in genetic disorders
CN114981442A (zh) 2019-12-04 2022-08-30 桑格摩生物治疗股份有限公司 用于生产重组aav的新颖组合物及方法
US20230103302A1 (en) * 2020-02-28 2023-04-06 Asahi Kasei Medical Co., Ltd. Method for evaluating viral clearance capability
JP2023521347A (ja) 2020-04-07 2023-05-24 ユニキュアー アイピー ビー．ブイ． アンジオポエチン様３（ａｎｇｐｔｌ３）をサイレンシングするための遺伝子構築物及びその使用
EP4305157A1 (en) 2021-03-09 2024-01-17 Huidagene Therapeutics (Singapore) Pte. Ltd. Engineered crispr/cas13 system and uses thereof
US20240157306A1 (en) * 2021-03-30 2024-05-16 3M Innovative Properties Company Hollow-fiber membrane and method making thereof
WO2022214635A1 (en) 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
CA3219847A1 (en) 2021-06-02 2022-12-08 Sander Jan Hendrik Van Deventer Adeno-associated virus vectors modified to bind high-density lipoprotein
EP4359525A1 (en) 2021-06-21 2024-05-01 uniQure biopharma B.V. Gene constructs for silencing alpha-synuclein and uses thereof
WO2022268811A1 (en) 2021-06-21 2022-12-29 Uniqure Biopharma B.V. Improved lysis procedures
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
WO2023198745A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of apoe
WO2023198702A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of c9orf72
WO2023198663A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of snca
WO2023198662A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Novel systems for nucleic acid regulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US6066324A (en) 1994-10-07 2000-05-23 Loyola University Of Chicago Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles
DE19709186C2 (de) * 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
CA2348382C (en) 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
AU2003212708A1 (en) 2002-03-05 2003-09-16 Stichting Voor De Technische Wetenschappen Baculovirus expression system
US20050009168A1 (en) * 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
CN101506369B (zh) * 2006-06-21 2014-02-12 尤尼克尔生物制药股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav-rep78翻译起始密码子的载体
US20080299545A1 (en) * 2007-03-06 2008-12-04 Shuyuan Zhang Chromatographic methods for assessing adenovirus purity
US20100323429A1 (en) * 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
WO2010148143A1 (en) 2009-06-16 2010-12-23 Genzyme Corporation Improved methods for purification of recombinant aav vectors
CN102947453A (zh) * 2010-01-28 2013-02-27 费城儿童医院 用于病毒载体纯化的可扩缩生产平台和用于基因治疗中的如此纯化的病毒载体
US9840694B2 (en) * 2011-09-08 2017-12-12 Uniqure Ip B.V. Removal of contaminating viruses from AAV preparations

Also Published As

Publication number Publication date
IL231398A0 (en) 2014-04-30
JP2018023365A (ja) 2018-02-15
DK2744895T3 (en) 2016-01-04
IL231398A (en) 2017-06-29
WO2013036118A1 (en) 2013-03-14
JP6198278B2 (ja) 2017-09-20
US9840694B2 (en) 2017-12-12
JP2014526246A (ja) 2014-10-06
ES2558168T3 (es) 2016-02-02
KR101961347B1 (ko) 2019-03-25
US10253301B2 (en) 2019-04-09
PT2744895E (pt) 2016-02-08
EA027511B1 (ru) 2017-08-31
EA201490583A1 (ru) 2014-07-30
HK1220229A1 (zh) 2017-04-28
CN107502597A (zh) 2017-12-22
EP2744895B1 (en) 2015-10-14
EP3425044A1 (en) 2019-01-09
ZA201401714B (en) 2015-12-23
HUE026579T2 (en) 2016-06-28
EP2990477B1 (en) 2018-08-29
AU2012304993A1 (en) 2014-03-20
MX2014002733A (es) 2014-07-14
KR20140074333A (ko) 2014-06-17
PL2744895T3 (pl) 2016-04-29
CA2847604A1 (en) 2013-03-14
US20190218523A1 (en) 2019-07-18
CN103857790A (zh) 2014-06-11
AU2012304993B2 (en) 2017-09-14
EP2990477B8 (en) 2018-10-31
US20180100143A1 (en) 2018-04-12
EP2744895A1 (en) 2014-06-25
US20140342434A1 (en) 2014-11-20
SI2744895T1 (sl) 2016-03-31
EP2990477A1 (en) 2016-03-02
BR112014005255A2 (pt) 2017-04-04
CN103857790B (zh) 2017-09-08
JP6624690B2 (ja) 2019-12-25

Similar Documents

Publication Publication Date Title
MX349601B (es) Remocion de virus contaminantes de preparaciones de aav.
HK1245140A1 (zh) 使用自然殺傷細胞治療血液病症、實體瘤或感染性疾病的方法
WO2014124087A8 (en) Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
EP4253403A3 (en) Zika virus purification
EP3291806A4 (en) Process to extract and purify delta-9-tetrahydrocannabinol
MX2016009965A (es) Produccion de alta titulacion de vectores virales adenoasociados.
EP3201336A4 (en) Methods for extracting and purifying non-denatured proteins
EP2996475A4 (en) Adeno-associated virus mediated gene transfer to the central nervous system
EP3236772A4 (en) Methods of purifying recombinant proteins
WO2013014294A3 (en) Improved baculovirus expression systems
EP3838921A3 (en) Antibodies to tau
PH12016502220A1 (en) Means and methods for treating cmv
IN2014DN08481A (es)
EP2938616A4 (en) PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
IN2012MU03723A (es)
MX369662B (es) Granulos de harina de microalgas y proceso de preparacion de estos.
EP3380611A4 (en) PRODUCTION OF VIRUSES IN A CELL CULTURE
EP3170894A4 (en) New undifferentiated stem cell removal and myocardial purification and refinement culture medium
SG11201405868YA (en) Steam cracking process and system with integral vapor-liquid separation
EP3116645A4 (en) Separation matrices for purification of biological particles
WO2013028334A3 (en) Use of small molecules in methods for purification of biomolecules
EA201792366A1 (ru) Способ разделения белка и прочих примесей и капсульных полисахаридов микроорганизмов
IN2015DN02772A (es)
WO2014102759A3 (en) Process for the preparation of dasatinib and its intermediates
EP2729394A4 (en) CLIP SEPARATION SYSTEM, ASSEMBLY ASSEMBLY, AND CORRESPONDING METHODS OF OPERATION AND ASSEMBLY RELATED THERETO

Legal Events

Date Code Title Description
FG Grant or registration